193 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

A paradigm shift in perception, learning and action - core of the second advice of the Committee Innovation Health Care Professions & Education

Translation of the core of the second advice of The Committee Innovation Health Care Professions & Education.

Report | 18-05-2017

Migalastat (Galafold) for the treatment of Fabry's disease

Zorginstituut Nederland carried out an assessment of whether, based on the criteria of the Medicines Reimbursement System...

Report | 25-04-2017

Elosulfase alfa (Vimizim) for the treatment of Morquio A syndrome

Zorginstituut Nederland carried out a reassessment of the medicinal product elosulfase alfa (Vimizim).

Report | 24-04-2017

Ibrutinib (Imbruvica®) for the treatment of chronic lymphatic leukaemia

Zorginstituut Nederland carried out an assessment of the medicinal product ibrutinib (Imbruvica®), for the first-line treatment...

Report | 24-04-2017

Cysteamine with delayed release (Procysbi®)

Zorginstituut Nederland carried out an assessment of the medicine cysteamine with delayed release (Procysbi®) whereby they...

Report | 23-03-2017

A paradigm shift in perception, learning and action - summary of the second advice of the Committee Innovation Health Care Professions & Education

Summary of the second report of The Committee Innovation Health Care Professions & Education.

Report | 23-03-2017

Daclizumab (Zinbryta) for the treatment of relapsing (recidive) forms of multiple sclerosis (RMS)

Zorginstituut Nederland carried out a marginal assessment of the medicine daclizumab (Zinbryta), whereby they came to the...

Report | 15-12-2016

Palbociclib (Ibrance) for the treatment of metastatic breast cancer

Zorginstituut Nederland carried out an assessment of the medicine palbociclib (Ibrance), whereby they came to the following...

Report | 15-12-2016

Netupitant - palonosetron (Akynzo®) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy

Zorginstituut Nederland has assessed the medicine netupitant/palonosetron (Akynzeo®), whereby they came to the following...

Report | 31-10-2016

Fingolimod (Gilenya)

Zorginstituut Nederland has advised on amending the conditional inclusion of the medicine fingolimod (Gilenya) in the Medicines...

Report | 08-07-2016